Early onset of antipsychotic action in schizophrenia: Evaluating the possibility of shorter acute efficacy trials

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 286-289

  Kinon, Bruce J ^a   Chen, Lei ^a   Stauffer, Virginia L ^a   Sniadecki, Jennifer ^a   Ascher Svanum, Haya ^a   Kollack Walker, Sara ^a   Jacob, Jayanthi ^a   Kapur, Shitij ^b  

^a ELI LILLY AND COMPANY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trials; Nonresponse; Olanzapine; Placebo; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; PLACEBO;

ADULT; AGED; ANTIPSYCHOTIC ACTIVITY; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EFFECT SIZE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952383269     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181dcb7c3     Document Type: Article

References (19)

1. Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active controlled clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62:1305-1312.
2. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: treatment of schizophrenia. J Clin Psychiatry. 1999;60(suppl 11):3-80.
3. Marder SR, Van-Kammen DP. Dopamine receptor antagonists. In: Kaplan HI, Saddock BJ, eds. Comprehensive Textbook of Psychiatry. Volume 2, 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2000:2356-2377.
4. Weijer C. Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary? Schizophr Res. 1999;35:211-218.
5. Wyatt RJ, Henter ID, Bartko JJ. The long term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry. 1999;46:1092-1105.
6. Carpenter WT Jr, Appelbaum PS, Levine RJ. The declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am J Psychiatry. 2003;160:356-362.
7. Levine RJ. The need to revise the Declaration of Helsinki. N Engl J Med. 1999;341:531-534.
8. Fleischhacker WW, Czobor P, Hummer M, et al. Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry. 2003;60:458-464.
9. McMahon RP, Kelly DL, Boggs DL, et al. Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr Bull. 2008;34:292-301.
10. Welge JA, Keck PE Jr. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl). 2003;166:1-10.
11. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
12. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124:159-167.
13. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
14. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60:1228-1235.
15. Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57:1543-1549.
16. Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005;162:939-946.
17. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230-240.
18. Correll CU, Malhotra AK, Kaushik S, et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160:2063-2065.
19. Glick ID, Bossie CA, Alphs L, et al. Onset and persistence of antipsychotic response in patients with schizophrenia. J Clin Psychopharmacol. 2009;29:542-547.